A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

CEO David Meeker highlighted progress in the Phase 3 trial for acquired hypothalamic obesity (HO) and confirmed plans to file with the FDA in Q3 2025. He expressed confidence in the potential of ...